Alan Gill

USPTO Granted Patents = 14 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 3.7

ph-index = 4

Forward Citations = 35(Granted Patents)

Company Filing History:

12 out of 17

Als Therapy Development Institute

Years Active: 2002-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275793 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders (2025-04-14),

2. 12157728 - Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions (2024-12-03),

3. 11708349 - Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions (2023-07-25),

4. 11692040 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders (2023-07-04),

5. 11660324 - Copper complexes for treatment of neurodegenerative disorders (2023-05-30),

6. 11014990 - Anti-CD40L antibodies (2021-05-25),

7. 10683356 - Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies (2020-06-16),

8. 10106618 - Anti-CD40L antibodies (2018-10-23),

9. 9044459 - Method for the treatment of neurodegenerative diseases (2015-06-02),

10. 8946301 - Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis (2015-02-03),

11. 8865645 - Method of treating lung fibrosis using ST2 polypeptide (2014-10-21),

12. 8673308 - Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases (2014-03-18),

13. 8435514 - Method for the treatment of neurodegenerative diseases (2013-05-07),

14. 6495525 - VLA-4 inhibitor: oMePUPA-V (2002-12-17),

Title: Alan Gill: Innovator in Neurological Treatments

Introduction

Alan Gill is a prominent inventor based in Reading, MA (US), known for his significant contributions to the field of medical research. With a total of 14 patents to his name, he has focused on developing innovative therapies for various diseases, particularly those related to neurological conditions.

Latest Patents

Among his latest patents, Alan has developed Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders. This invention includes anti-human CD40L antibodies engineered to lack the ability to activate platelets, providing new methods for treating patients with CD40L-associated diseases. Additionally, he has worked on targeting endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions. This patent discloses methods and therapeutic compositions for treating disorders such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease, utilizing Salubrinal analogs or their pharmaceutically acceptable salts, hydrates, or solvates.

Career Highlights

Alan has had a notable career, working with esteemed organizations such as ALS Therapy Development Institute and Biogen, Incorporated. His work has significantly impacted the development of treatments for complex neurological disorders, showcasing his dedication to advancing medical science.

Collaborations

Throughout his career, Alan has collaborated with several notable professionals, including Steven N Perrin and Fernando G Vieira. These partnerships have further enhanced his research and development efforts in the medical field.

Conclusion

Alan Gill's innovative work in developing therapies for neurological conditions highlights his commitment to improving patient outcomes. His contributions through patents and collaborations continue to shape the future of medical treatments.

This text is generated by artificial intelligence and may not be accurate.